MA34221B1 - Protéine de fusion robo1-fc et son utilisation dans le traitement des tumeurs - Google Patents

Protéine de fusion robo1-fc et son utilisation dans le traitement des tumeurs

Info

Publication number
MA34221B1
MA34221B1 MA35354A MA35354A MA34221B1 MA 34221 B1 MA34221 B1 MA 34221B1 MA 35354 A MA35354 A MA 35354A MA 35354 A MA35354 A MA 35354A MA 34221 B1 MA34221 B1 MA 34221B1
Authority
MA
Morocco
Prior art keywords
robo1
fusion protein
tumor treatment
protein
relates
Prior art date
Application number
MA35354A
Other languages
English (en)
Inventor
Francis Blanche
Beatrice Cameron
Tarik Dabdoubi
Frederique Dol-Gleizes
Pierre Fons
Jean-Pascal Herault
Catherine Prades
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42830780&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA34221(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of MA34221B1 publication Critical patent/MA34221B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/01—Hydrolysed proteins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Steroid Compounds (AREA)

Abstract

La présente invention concerne une protéine recombinante Robo1-Fc et son utilisation pour traiter les maladies dans lesquelles une protéine Slit est surexprimée, en particulier le cancer. Elle concerne également une composition comprenant une telle protéine recombinante. Un autre aspect de l'invention consiste en l'utilisation d'une molécule Robo1-Fc en tant qu'outil de diagnostic pour détecter la surexpression d'une molécule de la famille Slit chez un patient.
MA35354A 2010-04-14 2011-04-08 Protéine de fusion robo1-fc et son utilisation dans le traitement des tumeurs MA34221B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR1052829A FR2958936A1 (fr) 2010-04-14 2010-04-14 Proteine de fusion robo1-fc et son utilisation dans le traitement des tumeurs
PCT/FR2011/050811 WO2011128561A1 (fr) 2010-04-14 2011-04-08 Protéine de fusion robo1-fc et son utilisation dans le traitement des tumeurs

Publications (1)

Publication Number Publication Date
MA34221B1 true MA34221B1 (fr) 2013-05-02

Family

ID=42830780

Family Applications (1)

Application Number Title Priority Date Filing Date
MA35354A MA34221B1 (fr) 2010-04-14 2011-04-08 Protéine de fusion robo1-fc et son utilisation dans le traitement des tumeurs

Country Status (26)

Country Link
US (1) US9493529B2 (fr)
EP (1) EP2558489A1 (fr)
JP (1) JP5858442B2 (fr)
KR (1) KR20130059329A (fr)
CN (1) CN102884076A (fr)
AR (1) AR080891A1 (fr)
AU (1) AU2011239839B2 (fr)
BR (1) BR112012026020A2 (fr)
CA (1) CA2796303A1 (fr)
CL (1) CL2012002879A1 (fr)
CR (1) CR20120508A (fr)
DO (1) DOP2012000265A (fr)
EA (1) EA201291044A1 (fr)
EC (1) ECSP12012230A (fr)
FR (1) FR2958936A1 (fr)
GT (1) GT201200275A (fr)
IL (1) IL222382A (fr)
MA (1) MA34221B1 (fr)
MX (1) MX338981B (fr)
NI (1) NI201200155A (fr)
PE (1) PE20130199A1 (fr)
SG (1) SG184529A1 (fr)
TN (1) TN2012000473A1 (fr)
TW (1) TW201142024A (fr)
UY (1) UY33334A (fr)
WO (1) WO2011128561A1 (fr)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012085178A1 (fr) * 2010-12-23 2012-06-28 Sanofi Protéine hybrides robo1-fc à utiliser dans traitement d'hépatocarcinomes
MX351313B (es) 2012-01-05 2017-10-10 Boston Medical Ct Corp Señalización de slit-robo para diagnosis y tratamiento de enfermedad del riñón.
US11566082B2 (en) 2014-11-17 2023-01-31 Cytiva Bioprocess R&D Ab Mutated immunoglobulin-binding polypeptides
CN107298715B (zh) * 2016-04-15 2021-05-04 阿思科力(苏州)生物科技有限公司 Slit2D2-嵌合抗原受体及其应用
US10703774B2 (en) 2016-09-30 2020-07-07 Ge Healthcare Bioprocess R&D Ab Separation method
CN109311949B (zh) 2016-05-11 2022-09-16 思拓凡生物工艺研发有限公司 储存分离基质的方法
US10889615B2 (en) 2016-05-11 2021-01-12 Cytiva Bioprocess R&D Ab Mutated immunoglobulin-binding polypeptides
ES2909833T3 (es) 2016-05-11 2022-05-10 Cytiva Bioprocess R & D Ab Método de limpieza y/o desinfección de una matriz de separación
US10730908B2 (en) 2016-05-11 2020-08-04 Ge Healthcare Bioprocess R&D Ab Separation method
US10654887B2 (en) 2016-05-11 2020-05-19 Ge Healthcare Bio-Process R&D Ab Separation matrix
ES2874974T3 (es) 2016-05-11 2021-11-05 Cytiva Bioprocess R & D Ab Matriz de separación
AU2018278809B2 (en) * 2017-06-02 2022-03-31 Boston Medical Center Corporation Recombinant ROBO2 proteins, compositions, methods and uses thereof
US11406682B2 (en) 2017-08-24 2022-08-09 Bar-Ilan University Roundabout (Robo) receptor inhibitors and uses thereof
CA3136663A1 (fr) * 2019-04-23 2020-10-29 The Regents Of The University Of California Compositions et methodes utiles pour favoriser la production de lait

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6136310A (en) 1991-07-25 2000-10-24 Idec Pharmaceuticals Corporation Recombinant anti-CD4 antibodies for human therapy
US20060122373A1 (en) 1997-04-04 2006-06-08 Millennium Pharmaceuticals, Inc. Delta3, FTHMA-070, Tango85, Tango77, SPOIL,NEOKINE, Tango129 and integrin alpha subunit protein and nucleic acid molecules and uses thereof
AU729496B2 (en) * 1997-10-20 2001-02-01 Regents Of The University Of California, The Robo: a novel family of polypeptides and nucleic acids
NZ507063A (en) * 1998-04-02 2003-11-28 Rigel Pharmaceuticals Inc Self-dimerising peptides causing the formation of compact structures
WO2002010217A2 (fr) * 2000-08-02 2002-02-07 The Johns Hopkins University Profils d'expression de cellules endotheliales
PT1572169E (pt) 2002-03-08 2013-10-08 Shanghai Inst Biol Sciences Deteção e modulação da angiogénese mediada pela slit e roundabout (robo), e correspondentes utilizações
WO2005014818A1 (fr) * 2003-08-08 2005-02-17 Perseus Proteomics Inc. Gene surexprime dans le cancer
CA2553187A1 (fr) * 2004-01-28 2005-08-11 Syntonix Pharmaceuticals, Inc. Proteines de fusion heterodimere de l'hormone-fc stimulant les follicules (fsh-fc) utiles dans le traitement de l'infertilite
KR20140071452A (ko) * 2006-04-05 2014-06-11 애브비 바이오테크놀로지 리미티드 항체 정제
AR063975A1 (es) 2006-11-28 2009-03-04 Centelion Fusiones fc con receptor para fgf soluble modificadas con actividad biologica mejorada
EP2599791A1 (fr) * 2007-04-27 2013-06-05 Genentech, Inc. Anticorps anti-CD4 puissants, stables et non immunosuppresseurs
UY31309A1 (es) 2007-08-29 2009-03-31 Anticuerpos anti-cxcr5 humanizados, derivados de los mismos y su uso
EP2050764A1 (fr) 2007-10-15 2009-04-22 sanofi-aventis Nouveau format d'anticorps bispécifique polyvalent

Also Published As

Publication number Publication date
JP5858442B2 (ja) 2016-02-10
MX2012011822A (es) 2012-11-12
CL2012002879A1 (es) 2013-03-22
EP2558489A1 (fr) 2013-02-20
TN2012000473A1 (fr) 2014-01-30
UY33334A (es) 2011-12-01
US9493529B2 (en) 2016-11-15
AR080891A1 (es) 2012-05-16
AU2011239839A1 (en) 2012-11-08
NI201200155A (es) 2013-02-05
JP2013523172A (ja) 2013-06-17
CA2796303A1 (fr) 2011-10-20
DOP2012000265A (es) 2013-02-28
SG184529A1 (en) 2012-11-29
BR112012026020A2 (pt) 2016-06-28
KR20130059329A (ko) 2013-06-05
CR20120508A (es) 2012-11-01
EA201291044A1 (ru) 2013-04-30
US20130039912A1 (en) 2013-02-14
ECSP12012230A (es) 2012-11-30
FR2958936A1 (fr) 2011-10-21
IL222382A0 (en) 2012-12-31
TW201142024A (en) 2011-12-01
IL222382A (en) 2016-06-30
AU2011239839B2 (en) 2015-08-20
CN102884076A (zh) 2013-01-16
WO2011128561A1 (fr) 2011-10-20
MX338981B (es) 2016-05-06
PE20130199A1 (es) 2013-03-09
GT201200275A (es) 2014-01-24

Similar Documents

Publication Publication Date Title
MA34221B1 (fr) Protéine de fusion robo1-fc et son utilisation dans le traitement des tumeurs
WO2008101985A3 (fr) Séquences d'acides aminés dirigées contre le facteur de croissance de l'endothélium vasculaire et polypeptides comprenant ces séquences, pour le traitement de troubles et de maladies se caractérisant par une angiogenèse pathologique ou une néovascularisation
MY171100A (en) Anti-ceacam5 antibodies and uses thereof
WO2004108139A3 (fr) Utilisation de composes heterocycliques en tant qu'inhibiteurs de scce
EA200970403A1 (ru) Бициклические триазолы в качестве модуляторов протеинкиназы
MA33566B1 (fr) Thiohydantoïnes (hétéroarylméthyl) substituées utilisées comme médicaments anticancéreux
UA106194C2 (ru) Диагностика и лечение рака с применением антитела к ereg
AU2011338389A8 (en) Bicyclic compounds as Pim inhibitors
NO20055209D0 (no) Peptabody for cancerbehandling
EA201300242A1 (ru) Фармацевтические композиции, содержащие замещенные ациланилиды
MX2009004038A (es) Gel de diclofenaco.
MX2011010673A (es) Formulaciones de nanoparticulas y usos de las mismas.
WO2010066684A3 (fr) Inhibiteurs pyridyloxyindoles de vegf-r2 et utilisation thérapeutique de ceux-ci
TNSN07093A1 (en) Bicyclic amides as kinase inhibitors
CL2011003052A1 (es) Compuesto 8-(2,4-dimetoxi-pirimidin-5-il)-1-(1-etil-3-metil-1h-pirazol-4-il)-3-metil-1,3-dihidro-imidazo[4,5-c]quinolin-2-ona; su composicion farmaceutica; util en el tratamiento de enfermedades dependientes de la cinasa de lipido y/o de proteina, en el tratamiento de enfermedades proliferativas, tales como tumores y carcinomas de cerebro, riñon, higado, entre otras.
WO2009093119A3 (fr) Utilisation d'inhibiteurs de sérine protéases pour traiter des maladies de peau
GEP20125647B (en) Kinesin inhibitors as cancer therapeutics
EP2175879A4 (fr) Traitement de maladies associées à la protéine prion
ATE472998T1 (de) Kationische liposomale zubereitungen zur behandlung von rheumatoider arthritis
ATE506961T1 (de) Ccn3 proteine zur behandlung und diagnose von nierenerkrankungen
MXPA05011085A (es) Composiciones y metodos relacionados a stop-1.
MA34291B1 (fr) Compositions et méthodes de diagnostic et de traitement d'une tumeur
WO2010036031A3 (fr) Anticorps monoclonal humain specifique au pauf, composition pharmaceutique destinee au traitement du cancer le comprenant et procede l'utilisant pour detecter le cancer
MA37961A1 (fr) Nouveaux traitements thérapeutiques par anticorps anti-her2 à basse fucosylation
MA34480B1 (fr) Docosahexanoate de panthényle et son utilisation pour traiter et prévenir les maladies cardiovasculaires